BosleyMD® and Yuva Biosciences Unveil Groundbreaking Hair Loss Innovation After 25 Years

Cutting-edge technology that incorporates established research, natural compounds, and artificial intelligence is poised to revolutionize the way consumers combat age-related changes in hair and skin. Recent scientific studies have highlighted the pivotal role of mitochondria, often dubbed the powerhouse of cells, in various age-related transformations affecting hair, skin, and other bodily systems. Capitalizing on this research, Yuva Biosciences has harnessed the power of artificial intelligence to sift through a vast array of molecules and pinpoint YuvaBio® Y100™ as a groundbreaking ingredient capable of mitigating mitochondrial dysfunction. This breakthrough is now available for licensing to non-drug consumer brands.

Dr. Ken Washenik, Chief Medical Officer of Bosley, a leading authority in hair restoration solutions, expressed enthusiasm, stating, “

We believe this is one of the biggest innovations in hair loss we’ve seen in twenty-five years.” BosleyMD® is introducing its cutting-edge Revive Plus Densifying Foam, incorporating YuvaBio® Y100™ technology, for both men and women. This innovative product will be available at major national mass retailers, beauty chains, pharmacy chains, and e-commerce sites.

At the forefront of mitochondrial science is Dr. Keshav K. Singh, Chief Scientific Officer and Co-Founder of Yuva Biosciences. With a Harvard background and a prominent position as the Joy and Bill Harbert Endowed Chair and professor at the University of Alabama-Birmingham, Dr. Singh has been a driving force in mitochondrial research. As the founding Editor-in-Chief of the journal Mitochondrion and the founder of the Mitochondria Research and Medicine Society, he has authored over 100 scientific studies on mitochondria. Dr. Singh’s groundbreaking 2018 study made global headlines by establishing that mitochondrial dysfunction is a key cause of aging in hair and skin, and it can be reversed by restoring mitochondrial function. This pivotal discovery led to the inception of Yuva Biosciences in 2019 to address the challenge of developing consumer products that reverse mitochondrial decline. Yuva Biosciences experts utilized AI to identify molecules capable of restoring mitochondrial function, with Y100 being the first to hit the market from their pipeline.

The team at Yuva Biosciences boasts significant experience in translating scientific discoveries into consumer products. The CEO, Greg Schmergel, a serial entrepreneur with a background in nanotechnology, leads the team alongside Dr. Shekhar Mitra, a renowned leader in consumer products innovation. Dr. Mitra, the former Senior Vice President of Corporate Innovation at Procter & Gamble, played a pivotal role in the creation and development of globally successful products like Oil of Olay Regenerist, Crest Whitestrips, Crest ProHealth, Aleve Analgesic, Prilosec, and Old Spice Clinical Strength. Applauding Yuva Biosciences’ unique platform based on mitochondrial science, Dr. Mitra highlights its potential as a game-changer, evident in multiple clinical trials and now reflected in products available on store shelves.

In a noteworthy development, VentureSouth, one of the nation’s largest angel investment networks, spearheaded a $7.5M seed round for Yuva Biosciences. Matt Dunbar, Managing Director at VentureSouth, emphasized the significance of Yuva Biosciences’ technology in addressing the root cause of aging, mitochondrial dysfunction. He noted that while billions are spent annually on cosmetics targeting aging symptoms, Yuva Biosciences’ once-in-a-generation innovation stands out by tackling a key factor in the aging process.

Source Link